Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors
- PMID: 11585414
- DOI: 10.1006/gyno.2001.6308
Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors
Abstract
Objective: The aim of this study was to further evaluate whether the expression of p27(kip1), cyclin E, and cdk2 is related to the malignancy of ovarian tumors and whether their expressions, alone or in combination, are associated with prognosis in epithelial ovarian carcinoma.
Methods: Immunohistochemical analysis using anti-p27(kip1), anti-cyclinE, and anti-cdk2 antibodies was carried out for 103 cases consisting of benign, borderline, and malignant ovarian tumors, and Western blot analysis and cdk2 activity assay were performed in 26 fresh ovarian tumor samples.
Results: p27(kip1) expression was reduced in ovarian carcinomas in contrast to benign and borderline tumors. The expression of cyclin E and cdk2 gradually increased from benign to borderline to malignant tumors. Kaplan-Meier survival analysis showed that patients with p27(kip1) expression had a high overall survival rate. Patients with cyclin E overexpression had a low overall survival rate. When the combination of these proteins was analyzed, patients with the p27(kip1) (-)/cyclin E (++)/cdk2 (++) phenotype were significantly associated with the poorest overall survival. In multivariate Cox regression analysis, the combined phenotype of p27(kip1) (-)/cyclin E (++)/cdk2 (++) was independently related to poor prognosis.
Conclusions: Our results suggest that loss of p27(kip1) expression and overexpression of cyclin E or cdk2 were significantly associated with malignancy in ovarian tumors. p27(kip1) and cyclin E proteins may be valuable prognostic factors for epithelial ovarian carcinoma patients. Furthermore, the combined evaluation of p27(kip1)/cyclin E/cdk2 may provide the most important prognostic implication.
Copyright 2001 Academic Press.
Similar articles
-
The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors.Gynecol Oncol. 1999 May;73(2):202-9. doi: 10.1006/gyno.1999.5373. Gynecol Oncol. 1999. PMID: 10329035
-
Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.Int J Gynecol Pathol. 2011 May;30(3):205-17. doi: 10.1097/PGP.0b013e3182063e71. Int J Gynecol Pathol. 2011. PMID: 21464733
-
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer.Cancer Res. 1999 Aug 1;59(15):3790-4. Cancer Res. 1999. PMID: 10446997
-
Cdk2 as a master of S phase entry: fact or fake?Cell Cycle. 2004 Jan;3(1):35-7. Cell Cycle. 2004. PMID: 14657662 Review.
-
Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice.J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):55-66. doi: 10.1023/B:JOMG.0000023588.55733.84. J Mammary Gland Biol Neoplasia. 2004. PMID: 15082918 Review.
Cited by
-
The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers.Int J Mol Sci. 2024 Apr 5;25(7):4060. doi: 10.3390/ijms25074060. Int J Mol Sci. 2024. PMID: 38612869 Free PMC article.
-
Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer.Mol Carcinog. 2010 Feb;49(2):130-40. doi: 10.1002/mc.20582. Mol Carcinog. 2010. PMID: 19777567 Free PMC article.
-
Prognostic biomarkers in ovarian cancer.Cancer Biomark. 2010-2011;8(4-5):231-51. doi: 10.3233/CBM-2011-0212. Cancer Biomark. 2010. PMID: 22045356 Free PMC article. Review.
-
p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.Clin Cancer Res. 2011 Jan 1;17(1):12-8. doi: 10.1158/1078-0432.CCR-10-0752. Epub 2010 Oct 21. Clin Cancer Res. 2011. PMID: 20966355 Free PMC article. Review.
-
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.Oncotarget. 2015 Aug 28;6(25):20801-12. doi: 10.18632/oncotarget.4600. Oncotarget. 2015. PMID: 26204491 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous